NCT04303845View on ClinicalTrials.gov

Erenumab For Treatment of Hemicrania Continua

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions

Hemicrania Continua

Interventions

DRUG

Erenumab

140 mg of erenumab via subcutaneous injection

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER

NCT04303845 - Erenumab For Treatment of Hemicrania Continua | Biotech Hunter | Biotech Hunter